Navigation Links
Government Regulation of Drug Prices will Increase in Both Mature and Emerging Markets, Including Markets that Traditionally Play a Limited Role in Pharmaceutical Pricing
Date:12/8/2010

BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pharmaceutical industry must prepare itself for an increasingly draconian drug pricing environment. While governments in most of the world's developed economies already regulate the prices of most prescription drugs, their control over prices will tighten in the future. According to Decision Resources' new Industry Report, Pharmaceutical Pricing and Reimbursement: Key Facts in Mature and Emerging Markets, even some of the countries that traditionally play a limited role in price setting are poised to introduce stricter controls on pharmaceutical pricing in the future.

The German and United Kingdom governments, which have generally allowed manufacturers relative freedom to set the prices of new drugs, plan to introduce value-based pricing. The United States will continue to allow free pricing of pharmaceuticals, but recently enacted healthcare reform legislation will increase Medicaid rebates and require manufacturers to offer a 50 percent discount on drugs prescribed in the Medicare coverage gap.

"Increased pricing control efforts are not limited to mature markets—governments in emerging markets will also intensify their efforts," said Neil Grubert, M.A., director of pricing and reimbursement research at Decision Resources. "Governments in emerging markets will pay close attention to how proposed prices in their countries compare with prices in other major markets and may demand that manufacturers offer them prices that are lower than those in advanced economies."

The report also finds that substantial budget deficits will force many governments around the world to intensify their efforts to curb spending on healthcare services. Although prescription drugs typically account for only ten to 20 percent of total healthcare expenditures, governments can be expected to focus their cost-containment strategies disproportionately on the pharmaceutical industry.

"Increasingly, payers will limit the most generous reimbursement terms to drugs that have clear evidence of superiority over established therapies. Drugs that lack proof of innovation will be subject to reimbursement restrictions, unless manufacturers offer prices that are in line with, or below, the prices of competing medicines that are already on the market," said Grubert.

About this Industry ReportPharmaceutical Pricing and Reimbursement: Key Facts in Mature and Emerging Markets provides a concise overview of the essential elements of pharmaceutical pricing and reimbursement in 14 markets across the globe. For each of these countries, Decision Resources reviews key factors in market access, including health insurance, pharmaceutical pricing, reimbursement, cost containment, and health technology assessment. In addition, Decision Resources assesses the international outlook and implications for the pharmaceutical industry.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.Decision ResourcesLisa Osgood781-993-2606 losgood@dresources.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. States, Federal Government Could Save $30 Billion by Managing Medicaid Pharmacy More Like Medicare and Commercial Sector Programs
2. InteRNA Technologies Awarded EUR 1.3 Million Innovation Credit From Dutch Government
3. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
4. Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government
5. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
6. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
7. Cardiogenesis Receives Research Award From Federal Government
8. Local Chinese Government Authorities Approve Pricing and Reimbursement for NeoStems Licensed Adult Stem Cell Treatments for Orthopedic Applications in China
9. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
10. Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research
11. Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):